GATC Health enters the oncology drug market with a patent application “Prodrugs for the treatment of cancer”
IRVINE, Calif., April 20, 2022 /PRNewswire/ — GATC Health, a biotechnology company that is revolutionizing drug discovery and disease prediction using artificial intelligence and advanced multiomics, today announced that it has filed an application patent for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for the treatment of cancer. This breakthrough, produced by the company’s revolutionary Multiomics Advanced Technology™ AI platform, marks GATC Health’s entry into the oncology drug discovery market.
GATC Health’s unique new prodrug is designed to stimulate programmed cell death in malignant cancer tissue.
Prodrugs are biologically inactive compounds that are metabolized in the body to produce a drug. Examples include Aspirin, Plavix and Prednisone. GATC Health’s unique new prodrug is designed to stimulate programmed cell death in malignant cancer tissue and may serve as an effective therapeutic against glioblastoma brain tumors.
This novel treatment mechanism has not previously been possible due to the difficulty of providing and specifying target drug interactions and has the potential for an improved safety profile and improved selectivity. Additionally, this new prodrug format can significantly reduce the collateral damage caused by previous iterations of chemical agents used to treat cancers. The company expects this format to lead to many more breakthroughs in new cancer treatments.
“I am very pleased that we continue to expand our portfolio at GATC Health and enter oncology with this innovative platform to address the unmet needs of cancer patients,” said Preetaman Wadhwa, Chief Marketing Officer of the company. “Glioblastoma accounts for half of all cancerous brain tumors in adults. We see an average survival time of around 12-18 months for these patients, with only 5% of patients surviving more than five years, highlighting the unmet need for innovation for these patients. a new prodrug has the potential to differentiate between glioblastoma cells and healthy neuron growth, preventing cancer cell replication for glioblastoma. This new technology may also be used for other tumors. Global therapeutics spending and in cancer supportive care continue to grow and be is expected to achieve 200 billion dollars in 2022. With the increasing incidence of cancer in patients, oncology is the focus area of the top 10 pharmaceutical companies, and we look forward to partnering with them to provide glioblastoma patients and other cancer patients a safe and effective treatment.
About GATC Health
GATC Health Corp is a pioneering technology company that uses whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company’s patented AI platform reduces risk, time and cost for life science companies by digitally replicating the human body to find non-obvious answers to the most complex questions in biology. GATC Health is accelerating the transition of healthcare towards predictive and individualized medicine.
The information contained herein is presented for informational purposes only and should not be considered an offer to sell securities. This presentation contains information that the Company believes to be correct, including certain financial information and projections, but the Company does not warrant the accuracy or completeness of such information. The Company reserves the right to modify or amend the information contained in this document.
View original content for multimedia download: https://www.prnewswire.com/news-releases/gatc-health-enters-oncology-drug-market-with-prodrugs-for-cancer-treatment-patent-application-301529704 .html
SOURCE GATC Health Corp